12,375 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Bought by EntryPoint Capital LLC

EntryPoint Capital LLC purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 12,375 shares of the biotechnology company’s stock, valued at approximately $233,000.

A number of other hedge funds have also modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $38,000. Van ECK Associates Corp raised its position in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV lifted its stake in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 1,644 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at $149,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $190,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ARWR shares. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Sanford C. Bernstein decreased their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. Finally, B. Riley restated a “buy” rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Hold” and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Stock Up 0.1 %

Shares of ARWR opened at $13.82 on Friday. The stock has a 50 day moving average price of $18.13 and a 200 day moving average price of $19.62. Arrowhead Pharmaceuticals, Inc. has a one year low of $13.66 and a one year high of $30.41. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, COO Patrick O’brien sold 29,184 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $578,426.88. Following the transaction, the chief operating officer now owns 535,201 shares of the company’s stock, valued at approximately $10,607,683.82. The trade was a 5.17 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total transaction of $219,456.00. Following the sale, the chief executive officer now owns 3,764,252 shares of the company’s stock, valued at approximately $71,709,000.60. The trade was a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 286,317 shares of company stock valued at $5,049,735. Corporate insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.